ClinicalTrials.gg
TerminatedNCT03630393UltralowUpdated Feb 18, 2022Results posted

Ultralow Versus Standard Pneumoperitoneum Pressure

An interventional study of Pneumoperitoneum Pressure 6 mmHg and Pneumoperitoneum Pressure 15 mmHg in Prostate Cancer, sponsored by OhioHealth. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by OhioHealth · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
PI left institution

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
607th of 3,024
170 · median 48
Started
2019
with 159 others
No phase
764 of 3,597
157 open now
Registered
2,263rd of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 607th largest by enrollment of the 3,024 interventional ones that give a count, is one of 160 that started in 2019, is one of 764 with no phase, and was the 2,263rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The investigators plan to compare insufflation pressures during robotic assisted laparoscopic prostatectomy (RALP). Standard pressure is typically 15 mmHg, while in a previous study the investigators determined that 6 mmHg is possible routinely. Therefore, the investigators plan to compare the clinical outcomes of participants at a pneumoperitoneal pressure of 15 versus 6 mmHg.

Read the detailed description

The investigators to examine the impact of low pressure during robotic assisted laparoscopic prostatectomy (RALP) with the intention of identifying whether lower pressures might benefit participants. The investigators hypothesize that a low insufflation pressure may provide an improvement in postoperative pain and abdominal distension in addition to potential physiologic benefits, and that these factors might then allow a shorter hospital stay. The investigators previously initiated a protocol in September of 2016 (IRB# 1066864) to perform RALPs at an insufflation pressure of 6 mmHg with the intention of increasing the pressure as needed on an individual participant level. In order to determine whether this might allow earlier discharge when successful, the investigators began allowing for same-day discharge in participants meeting appropriate criteria. Having now demonstrated feasibility in over 300 consecutive participants using this ultralow pneumoperitoneum protocol, the investigators now plan to conduct a randomized trial to compare a pressure of 6 mmHg with participants having RALP at a standard pressure of 15 mmHg to determine whether there is a true benefit.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostatectomy
  • Robotic
  • Urology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 or older
  2. Diagnosed with prostate cancer
  3. Electing to undergo robotic assisted laparoscopic prostatectomy (RALP)

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18
  2. Emergency surgery
  3. Patients with a significant preoperative dependence on narcotic medications
  4. Unable to give
  5. Dementia, history of dementia, or other significant mental impairment that would, in the opinion of the investigator, impede patient self-reporting
  6. Persons participating in any other research study involving an drug or device or investigational surgical procedure that could interfere with the physiologic parameters being collected (for example, a study evaluating different anesthesia regimens that could confound study results)
  7. Non-English-speaking or reading
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Pressure 6 mmHg

    Pneumoperitoneum Pressure 6 mmHg

    Other: Pneumoperitoneum Pressure 6 mmHg

  • Active comparator
    Pressure 15 mmHg

    Pneumoperitoneum Pressure 15 mmHg

    Other: Pneumoperitoneum Pressure 15 mmHg

Interventions

  • OtherPneumoperitoneum Pressure 6 mmHg

    A pneumoperitoneum insufflation pressure of 6 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).

  • OtherPneumoperitoneum Pressure 15 mmHg

    A pneumoperitoneum insufflation pressure of 15 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Medication Use

    The cumulative dose (milligrams) of each opioid medication administered was calculated and converted to milligram morphine equivalents (MME) for each participant.

    Time frame: Through 1 week postoperatively

Secondary outcomes

  1. Post Operative Pain Scores

    Each participant was asked to rate their pain on a 0-10 scale, with higher numbers representing worse pain. Patients rated their pain at the following time points: in the post-anesthesia care unit (PACU) upon waking from anesthesia, at hours 4, 12, 16, and 20 after transfer to the floor, and immediately prior to discharge. The pain scores for each patient were averaged.

    Time frame: Through discharge (post-operative day 0 or post-operative day 1)

  2. Operative Ventilation

    Average tidal volume (ml)

    Time frame: Intraoperatively

  3. Discharge Day (Post-operative Day 0 or 1)

    The day of discharge (post-operative day 0 or post-operative day 1) was recorded for each participant

    Time frame: Through discharge (post-operative day 0 or 1)

07

Results

Posted Feb 18, 2022

Participant flow

Participant flow — Overall Study
MilestonePressure 6 mmHgPressure 15 mmHg
Started6871
Completed6771
Not completed10
Withdrew: Death10

Outcome measures

PrimaryPostoperative Pain Medication Use

The cumulative dose (milligrams) of each opioid medication administered was calculated and converted to milligram morphine equivalents (MME) for each participant.

Time frame:
Through 1 week postoperatively
Reported as:
Mean · morphine milligram equivalents
Postoperative Pain Medication Use
morphine milligram equivalentsPressure 6 mmHgPressure 15 mmHg
Postoperative Pain Medication Use56.6 ± 40.7261.2 ± 37.33
SecondaryPost Operative Pain Scores

Each participant was asked to rate their pain on a 0-10 scale, with higher numbers representing worse pain. Patients rated their pain at the following time points: in the post-anesthesia care unit (PACU) upon waking from anesthesia, at hours 4, 12, 16, and 20 after transfer to the floor, and immediately prior to discharge. The pain scores for each patient were averaged.

Time frame:
Through discharge (post-operative day 0 or post-operative day 1)
Reported as:
Mean · Units on a scale
Post Operative Pain Scores
Units on a scalePressure 6 mmHgPressure 15 mmHg
Post Operative Pain Scores1.4 ± 1.611.8 ± 1.86
SecondaryOperative Ventilation

Average tidal volume (ml)

Time frame:
Intraoperatively
Reported as:
Mean · milliliters
Operative Ventilation
millilitersPressure 6 mmHgPressure 15 mmHg
Operative Ventilation629.1 ± 81.9629.4 ± 83.1
SecondaryDischarge Day (Post-operative Day 0 or 1)

The day of discharge (post-operative day 0 or post-operative day 1) was recorded for each participant

Time frame:
Through discharge (post-operative day 0 or 1)
Reported as:
Count of participants · Participants
Discharge Day (Post-operative Day 0 or 1)
ParticipantsPressure 6 mmHgPressure 15 mmHg
Discharged on Post-operative day 05662
Discharged on Post-operative day 1118

Adverse events

Collected over Events were tracked through 90 days following discharge via review of medical records. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pressure 6 mmHg1/68 (1.5%)1/68 (1.5%)0/68 (0%)
Pressure 15 mmHg0/71 (0%)0/71 (0%)0/71 (0%)
Most frequent serious events
Most frequent serious events
EventPressure 6 mmHgPressure 15 mmHg
Epigastric bleedGastrointestinal disorders1/680/71

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pressure 6 mmHgPressure 15 mmHgTotal
Mean64.2 ± 6.5262.8 ± 6.6763.5 ± 6.61
Sex: Female, Male
Sex: Female, Male(Participants)Pressure 6 mmHgPressure 15 mmHgTotal
Female000
Male6871139
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Pressure 6 mmHgPressure 15 mmHgTotal
Count of participants——0
08

Study locations

1 site
  • Dublin Methodist Hospital
    Columbus, Ohio 43016, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Feb 2021, 21 months.

Results were first posted in Feb 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2018
First posted
Aug 14, 2018
StartActual
May 9, 2019
Primary completionActual
Feb 10, 2021
CompletionActual
Feb 10, 2021
Results first posted
Feb 18, 2022
Last update
Feb 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03630393
Lead sponsor
OhioHealth
Collaborators
CONMED Corporation
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
May 9, 2019
Primary completion
Feb 10, 2021
Completion
Feb 10, 2021
Results posted
Feb 18, 2022
Last update
Feb 18, 2022

Study contacts

Ronney Abaza, MD
principal investigator · OhioHealth

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion